Analyst Reco. Exact Sciences Corporation

Equities

EXAS

US30063P1057

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
58.85 ^USD	+0.10%		-3.46%	-20.45%

17/04	Exact Sciences Corporation announced that it has received $266.75 million in funding	CI
15/04	Sector Update: Health Care Stocks Advance Premarket Monday	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Benchmark Upgrades Exact Sciences to Buy From Hold, Sets Price Target at $91	02/01	MT
Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating	03/11	MT
BofA Securities Cuts Price Target on Exact Sciences to $88 From $110, Maintains Buy Rating	20/23/20	MT
Piper Sandler Upgrades Exact Sciences to Overweight From Neutral, Price Target is $90	10/23/10	MT
Bernstein Starts Exact Sciences With Outperform Rating	28/23/28	MT
Baird Adjusts Price Target on Exact Sciences to $121 From $99, Maintains Outperform Rating	02/23/02	MT
Benchmark Downgrades Exact Sciences to Hold From Buy	02/23/02	MT
Credit Suisse Adjusts Exact Sciences' Price Target to $90 From $75, Keeps Neutral Rating	02/23/02	MT
Goldman Sachs Adjusts Price Target on Exact Sciences to $110 From $85, Maintains Buy Rating	21/23/21	MT
UBS Raises Exact Sciences' Price Target to $99 From $73, Maintains Neutral Rating	27/23/27	MT
Canaccord Genuity Raises Price Target on Exact Sciences to $115 From $92, Maintains Buy Rating	23/23/23	MT
ANALYST RECOMMENDATIONS : BAE Systems, Berkeley, Burberry, Reinsurance Group, Tesla...	23/23/23
Citigroup Adjusts Price Target on Exact Sciences to $130 From $100, Keeps Buy Rating	22/23/22	MT
Exact Sciences says its new colon cancer test shows 30% lower false positive rate	21/23/21	RE
Jefferies Raises Exact Sciences' Price Target to $100 From $82, Maintains Buy Rating	07/23/07	MT
Citigroup Adjusts Price Target on Exact Sciences to $100 From $90, Maintains Buy Rating	11/23/11	MT
Baird Adjusts Price Target on Exact Sciences to $99 From $92, Maintains Outperform Rating	10/23/10	MT
BofA Adjusts Price Target on Exact Sciences to $88 From $80, Keeps Buy Rating	10/23/10	MT
Credit Suisse Raises Exact Sciences' PT to $75 From $70, Notes Broad-based Momentum, Guide Upgrade; Keeps Neutral Rating	10/23/10	MT
Craig Hallum Upgrades Exact Sciences to Buy From Hold, Raises Price Target to $85 From $55	10/23/10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Exact Sciences Corporation

Equities

EXAS

US30063P1057

Analyst Reco.

Filters